CD20-positive infiltrates in renal allograft biopsies with acute cellular rejection are not associated with worse graft survival

Serena M Bagnasco, W. Tsai, M Hafizur Rahman, Edward Kraus, L. Barisoni, R. Vega, Lorraine C Racusen, M. Haas, B. S. Mohammed, A. A. Zachary, R. A. Montgomery

Research output: Contribution to journalArticle


We examined rejection outcome and graft survival in 58 adult patients with acute cellular rejection Banff type I (ARI) or II (ARII), within 1 year after transplantation, with or without CD20-positive infiltrates. Antibody-mediated rejection was not examined. Of the 74 allograft biopsies, performed from 1999 to 2001, 40 biopsies showed ARI and 34 biopsies showed ARII; 30% of all the biopsies showed CD20-positive clusters with more than 100 cells, 9% with more than 200 cells and 5% with more than 275 cells. Patients with B cell-rich (>100 or >200/HPF CD20-positive cells) and B cell-poor biopsies ( 100/HPF) and B cell-poor were not significantly different at rejection, or at 1, 3, 6 and 12 months, and during additional 3 years follow-up after rejection, although higher creatinine at 1 year was noted in the >200/HPF group. Graft survival was also not different between B cell-rich and B cell-poor groups (p = 0.8 for >100/HPF, p = 0.9 for >200/HPF CD20-positive cells). Our data do not support association of B cell-rich infiltrates in allograft biopsies and worse outcome in acute rejection type I or II, but do not exclude the possible contribution of B cells to allograft rejection.

Original languageEnglish (US)
Pages (from-to)1968-1973
Number of pages6
JournalAmerican Journal of Transplantation
Issue number8
Publication statusPublished - Aug 2007



  • Acute rejection
  • B cells
  • CD20
  • Renal biopsy
  • Renal transplantation

ASJC Scopus subject areas

  • Immunology

Cite this